Get market insights delivered to your inbox
Search news, brands, technology

MIT Develops a Synthetic Gene Circuit to Trigger Immune System Attack on Cancer

MIT researchers have developed a synthetic gene circuit that triggers the body’s immune system to attack cancers when it detects signs of the disease....

DBV peanut allergy vaccine fails trial, but analysts say don’t write it off yet

DBV Technologies’ peanut allergy vaccine missed the mark—by a whisker—in a phase 3 trial but is still at least 50:50 for FDA approval, say...

Lilly, CureVac pen $1.8B mRNA cancer vaccine deal

Eli Lilly is putting up $1.8 billion to work with CureVac on five mRNA cancer vaccines. The back-loaded deal moves Lilly into an emerging field...

NIH public-private PACT aims to fire the Cancer Moonshot boosters

The National Institutes of Health (NIH) has enlisted the help of 11 top-tier biopharma companies as it pushes towards the goal of cutting the...

People may expect more side effects from pricier drugs

The placebo effect, in which a patient’s expectations lead them to experience the benefits of a treatment despite not actually receiving an active drug,...

Large, crystalline lipid scaffolds bring new possibilities to protein, drug research

Proteins and drugs are often attached to lipids to promote crystallization or ensure delivery to targeted tissues within the body, but only the smallest...

Biotech researchers chart progress in fighting substance abuse

As the opioid crisis broadens by the day, the biotech community is doubling down on its efforts to solve the mystery of addiction—and find...

Pfizer launches upstart with $103M, phase 3-ready meds

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them...

First biotech emerges from Garabedian’s accelerator, plans to tackle autoimmune diseases

Chris Garabedian’s accelerator has spawned its first biotech. The startup, Landos Biopharma, has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million...

BridgeBio Pharma gains $135M for genetic disease work

Early-stage Californian biotech BridgeBio Pharma has got off a $135 million financing round as it looks to push deeper into genetic disease R&D. The company...